What is the half-life of Risperdal (risperidone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Risperdal (Risperidone)

The half-life of risperidone is approximately 3 hours in extensive metabolizers and 20 hours in poor metabolizers, but the clinically relevant active moiety (risperidone plus its equipotent metabolite 9-hydroxyrisperidone) has an overall mean elimination half-life of approximately 20-23 hours, allowing for once or twice-daily dosing. 1

Pharmacokinetic Details by Metabolizer Status

The half-life of risperidone varies significantly based on CYP2D6 metabolizer status:

  • Extensive metabolizers (most patients): Risperidone half-life is approximately 3 hours (CV=30%), while 9-hydroxyrisperidone half-life is approximately 21 hours (CV=20%) 1
  • Poor metabolizers (6-8% of Caucasians, very low percentage of Asians): Risperidone half-life extends to approximately 20 hours (CV=40%), while 9-hydroxyrisperidone half-life is approximately 30 hours (CV=25%) 1

Clinical Significance of the Active Moiety

The combined half-life of the active moiety (risperidone plus 9-hydroxyrisperidone) is what matters clinically, averaging 20-23 hours across all metabolizer types. 1, 2

This is critical because:

  • 9-hydroxyrisperidone has similar pharmacological activity to the parent compound 1, 3
  • The clinical effect results from combined concentrations of both compounds 1
  • The pharmacokinetics of the combined active moiety are similar in extensive and poor metabolizers after single and multiple doses 1, 4

Dosing Implications

The 20-23 hour half-life of the active moiety supports:

  • Twice-daily or once-daily dosing schedules 2
  • Steady-state achievement in approximately 5-7 days (approximately 5 half-lives) 5
  • When switching from risperidone, cross-titration should account for this half-life 6

Special Population Considerations

In elderly patients, elimination half-lives are prolonged compared to young healthy subjects due to decreased renal clearance of both risperidone and 9-hydroxyrisperidone, requiring dose modifications. 1

In pediatric patients, pharmacokinetics are similar to adults after correcting for body weight differences 1

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.